Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study

Journal of Neurology

Volumn 263, Issue 9, 2016, Pages 1727-1735

  Annovazzi, Pietro ^a   Capobianco, M ^b   Moiola, L ^c   Patti, F ^d   Frau, J ^d   Uccelli, A ^e   Centonze, D ^f,g   Perini, P ^h   Tortorella, C ⁱ   Prosperini, L ^j   Lus, G ^k   Fuiani, A ^l   Falcini, M ^m   Martinelli, V ^c   Comi, G ^a,c   Ghezzi, A ^a  

^a ASST Valle Olona   (Italy)

^b SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^c VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF GENOA   (Italy)

^f IRCCS NEUROMED   (Italy)

^g UNIVERSITY OF ROME TOR VERGATA   (Italy)

^h UNIVERSITY OF PADOVA   (Italy)

ⁱ UNIVERSITY OF BARI   (Italy)

^j SAPIENZA UNIVERSITY OF ROME   (Italy)

^k SECOND UNIVERSITY OF NAPLES   (Italy)

^l GENERAL HOSPITAL   (Italy)

^m MISERICORDIA E DOLCE HOSPITAL   (Italy)

more..

Author keywords

Devic s syndrome; Dosing regimen; Neuromyelitis optica; Rituximab

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; GLATIRAMER; INTERFERON; MITOXANTRONE; MYCOPHENOLIC ACID; RITUXIMAB; TOCILIZUMAB; IMMUNOLOGIC FACTOR;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISEASE DURATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); MYELOOPTIC NEUROPATHY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RECURRENCE RISK; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; URINARY TRACT INFECTION; CLINICAL TRIAL; DISABILITY; ITALY; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; TREATMENT OUTCOME;

DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; ITALY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES; RITUXIMAB; TREATMENT OUTCOME;

EID: 84973665403     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-016-8188-y     Document Type: Article

References (43)

1. Wingerchuk DM, Banwell B, Bennett JL et al (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189
2. Wingerchuk DM, Weinshenker BG (2014) Neuromyelitis optica (Devic’s syndrome). Handb Clin Neurol 122:581–599
3. Sellnera J, Boggild M, Clanet M et al (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 17:1019–1032
4. Kimbrough DJ, Fujihara K, Jacob A et al (2012) Treatment of neuromyelitis optica: review and recommendations. Mult Scler Relat Disord 1:180–187
5. Pescovitz MD (2006) Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 5:859–866
6. Weiner GJ (2010) Rituximab: mechanism of action. Semin Haematol 47:115–123
7. Lucchinetti CF, Guo Y, Popescu BF, Fujihara K, Itoyama Y, Misu T (2014) The pathology of an autoimmune astrocytopathy: lessons learned from neuromyelitis optica. Brain Pathol 24:83–97
8. Cree BA, Lamb S, Morgan K, Chen A, Waubant E, Genain C (2005) An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64:1270–1272
9. Capobianco M, Malucchi S, di Sapio A et al (2007) Variable responses to rituximab treatment in neuromyelitis optica (Devic’s disease). Neurol Sci 28:209–211
10. Jacob A, Weinshenker BG, Violich I et al (2008) Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 65:1443–1448
11. Bedi GS, Brown AD, Delgado SR, Usmani N, Lam BL, Sheremata WA (2011) Impact of rituximab on relapse rate and disability in neuromyelitis optica. Mult Scler 17:1225–1230
12. Bomprezzi R, Postevka E, Campagnolo D, Vollmer TL (2011) A review of cases of neuromyelitis optica. Neurologist 17:98–104
13. Pellkofer HL, Krumbholz M, Berthele A et al (2011) Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology 76:1310–1315
14. Greenberg BM, Graves D, Remington G et al (2012) Rituximab dosing and monitoring strategies in neuromyelitis optica: creating strategies for therapeutic success. Mult Scler 18:1022–1026
15. Lindsey JW, Meulmester KM, Brod SA, Nelson F, Wolinsky JS (2012) Variable results after rituximab in neuromyelitis optica. J Neurol Sci 317:103–105
16. Ip VH, Lau AY, Au LW et al (2013) Rituximab reduces attacks in Chinese patients with neuromyelitis optica spectrum disorders. J Neurol Sci 324:38–39
17. Kim SH, Huh SY, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with Neuromyelitis Optica spectrum disorder. JAMA Neurol 70:1110–1117
18. Yang CS, Yang L, Li T et al (2013) Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica. Neurology 81:710–713
19. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71:324–330
20. Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, Dahodwala N (2015) Analysis of the treatment of neuromyelitis optica. J Neurol Sci 351:31–35
21. Radaelli M, Moiola L, Sangalli F et al. (2016) Neuromyelitis optica spectrum disorders: long-term safety and efficacy of rituximab in caucasian patients. Mult Scler 22(4):511–519. doi:10.1177/1352458515594042
22. Collongues N, Brassat D, Maillart E, et al. (2015) Efficacy of rituximab in refractory neuromyelitis optica. Mult Scler 22(7):955–959. doi: 10.1177/1352458515602337
23. Zèphir H, Bernard-Valnet R, Lebrun C et al (2015) Rituximab as first-line therapy in Neuromyelitis optica: efficiency and tolerability. J Neurol 262:2329–2335
24. Kim SH, Jeong IH, Hyun JW et al. (2015) Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab. JAMA Neurol 72(9):989–995. doi:10.1001/jamaneurol.2015.1276
25. Hauser SL, Waubant E, Arnold DL et al (2015) B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 358:676–688
26. Del Poeta G, Del Principe MI, Buccisano F et al (2008) Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 112:119–128
27. Miravalle AA, Kinkel R, Langer-Gould A et al. (2009) B Cell depletion and safety of low dose Rituximab in patients with Relapsing Remitting Multiple Sclerosis. Presented at the LXI AAN congress; Seattle, WA
28. Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an Expanded Disability Status Scale (EDSS). Neurology 33:1444–1452
29. Wingerchuck DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66:1485–1489
30. World Medical Association (2013) World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310:2191–2194
31. Kitley J, Elsone L, George J et al (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. JNNP 84:918–921
32. Ramanathan RS, Malhotra K, Scott T (2014) Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate. BMC Neurol 14:51
33. Provan D, Butler T, Evangelista ML et al (2007) Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. Haematologica 92:1695–1698
34. Blum S, Gillis D, Brown H et al (2010) Use and monitoring of low dose rituximab in myasthenia gravis. J Neurol Neurosurg Psychiatry 82:659–663
35. Chay J, Donovan P, Cummins L, Kubler P, Pillans P (2013) Experience with low-dose rituximab in off-label indications at two tertiary hospitals. Intern Med J 43:871–882
36. Bredemeier M, de Oliveira FK, Rocha CM (2014) Low- versus high-dose rituximab for rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res 66:228–235
37. Bredemeier M, Campos GG, de Oliveira FK (2015) Updated systematic review and meta-analysis of randomized controlled trials comparing low- versus high-dose rituximab for rheumatoid arthritis. Clin Rheumatol 34:1801–1805
38. Van Vollenhoven RF, Emery P, Bingham CO 3rd et al (2013) Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 72:1496–1502
39. Lan L, Han F, Chen JH (2012) Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B 13:731–744
40. Molloy ES, Calabrese LH (2012) Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum 64:3043–3051
41. Etemadifar M, Nasr Z, Khalili B, Taherioun M, Vosoughi R (2015) Epidemiology of neuromyelitis optica in the world: a systematic review and meta-analysis. Mult Scler Int 2015:174720. doi:10.1155/2015/174720
42. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53:1107–1114
43. Weinshenker BG, Barron G, Behne JM et al (2015) Challenges and opportunities in designing clinical trials for neuromyelitis optica. Neurology 84:1805–1815